Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffer Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults

NCT05547438
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
NTS-104 TRIS, Placebo
Drug
Lead sponsor
NeuroTrauma Sciences, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04870138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

NCT03701555
View directory record Official record
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children

NCT00444756
View directory record Official record
Conditions
Pain
Interventions
J-tip jet injection of 1% buffered lidocaine
Procedure
Lead sponsor
Norton Healthcare
Other
Eligibility
8 Years to 15 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 8, 2007 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

NCT02682927
View directory record Official record
Conditions
Dravet Syndrome, Seizure Disorder
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media

NCT02527642
View directory record Official record
Conditions
Infertility
Interventions
embryo culture in buffered media
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 23, 2026, 1:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

NCT05196061
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Questionnaire, Stool sample, Skin swab, Oral rinse
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CVD 909 Vi Prime Boost Study

NCT00326443
View directory record Official record
Conditions
Typhoid Fever
Interventions
CVD 909, Placebo, Vi Polysaccharide
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 1:33 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA®4 for Midface Volume Deficiency

NCT05133739
View directory record Official record
Conditions
Cheek Augmentation, Correction of Age-related Midface Contour Deficiencies
Interventions
injection of RHA®4 in Midface, injection of Comparator Product in Midface
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis

NCT05227300
View directory record Official record
Conditions
Symptomatic Irreversible Pulpitis
Interventions
Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution, 2% lidocaine with 1:100,000 epinephrine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Effect of an Antiseptic Solution on the Skin Microbiome

NCT05608382
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
sterile Phosphate Buffer Saline, SGW13
Other
Lead sponsor
Center for Innovation and Research Organization
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Subcutaneous Injection in Healthy Participants

NCT06516913
View directory record Official record
Conditions
Healthy
Interventions
Harvard Apparatus syringe pump
Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
22 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 23, 2026, 1:33 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327
View directory record Official record
Conditions
Scar, Wound Healing
Interventions
SLI-F06
Drug
Lead sponsor
Scarless Laboratories, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Encinitas, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 1:33 PM EDT
Withdrawn Phase 2 Interventional

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

NCT03843710
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT01502124
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
21
States / cities
Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 23, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Deciphering Preserved Autonomic Function After Multiple Sclerosis

NCT07012135
View directory record Official record
Conditions
Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Interventions
Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

NCT04801420
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
19
States / cities
Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

NCT02683928
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GBR 830, Placebo
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 23, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows

NCT04577898
View directory record Official record
Conditions
Infra-orbital Hollows, Tear-trough Deformity, Wrinkle
Interventions
RHA® Redensity Eye
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
248 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
4
States / cities
Encino, California • Santa Monica, California • Coral Gables, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 1:33 PM EDT
Withdrawn Not applicable Interventional

Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients

NCT00663975
View directory record Official record
Conditions
Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
DCI 1020
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
Up to 2 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 23, 2026, 1:33 PM EDT